SYBX
Synlogic·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 2
Ample Liquidity
Significant Revenue Decline
Significant Net Income Decline
EPS Beats Expectation
RSI Oversold
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About SYBX
Synlogic, Inc.
A biotech company developing synthetic biology-based therapeutics for various diseases
PO Box 30, Winchester, MA 01890
--
Synlogic, Inc., formerly known as "Mirna Therapeutics, Inc.", was established in Delaware in late 2007. The company is a clinical-stage biopharmaceutical company focused on advancing its drug discovery and development platform for synthetic biopharmaceuticals, which is designed to utilize synthetic biology to genetically reprogram beneficial microorganisms to treat metabolic and inflammatory diseases as well as cancer. Synthetic biopharmaceuticals are generated from proprietary drug discovery and development platforms, applying the principles and tools of synthetic biology to design beneficial probiotics to perform or provide critical therapeutic functions.
Company Financials
EPS
SYBX has released its 2024 Q1 earnings. EPS was reported at -2.6, versus the expected -0.82, missing expectations. The chart below visualizes how SYBX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
